Interferons for malignant blood diseases?

Haemolysis in Malignant Blood Diseases.

Interferons as therapeutic agents for infectious diseases.

This article explains the rationale for development of interferons as therapeutic agents, and describes commercial products available today. It also provides a summary of studies that have been performed with interferons for use as exogenous biological response modifiers in viral infections. Overall, the best data exist for treatment of viral hepatitis B and C, for which interferons are a corne...

Interferons and their application in lung diseases.

We enjoyed the comprehensive review on the potential therapeutic applications of interferon (IFN) in pulmonary diseases by Antoniou and associates (January 2003).1 Here, we would like to extend the conditions responsive to IFN treatment to include the Churg-Strauss syndrome (CSS). The CSS is an uncommon type of eosinophilic granulomatous inflammation with associated vascular necrosis accompanie...

Blood plasma pseudouridine in patients with malignant proliferative diseases.

The blood plasma concentration of pseudouridine was estimated in 104 healthy adult subjects, and 108 patients suffering from malignant proliferative diseases. The HPLC method for simultaneous determination of pseudouridine and creatinine was applied. The average physiological concentration of pseudouridine in blood plasma was 2.43 +/- 0.97 mumol.l-1 or 29.15 +/- 7.40 mmol.mol-1 creatinine. The ...

The role of interferons in the treatment of malignant neoplasms.

Interferons (IFNs) are proteins with a wide range of biological effects. IFNs have antiviral and antiproliferative properties. They modulate both the immune system and the expression of cell phenotype. In the past decade, the IFNs have received intense clinical scrutiny. Alpha IFN is the best studied and displays activity in many neoplastic diseases; it has shown the most promise in the hematol...